XNK Therapeutics adds three scientific advisors to bolster platform technology
XNK Therapeutics AB (“XNK”) today announced the strengthening of the company’s expertise by the appointment of Ola Landgren, M.D., Ph.D., Fredrik Schjesvold M.D., Ph.D. and Johan Lund M.D., Ph.D. These scientific advisors are key to the company’s plan to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies within plasma cell disorders and hematological malignancies.Dr. Ola Landgren joins with more than 30 years of medical experience. He serves as Professor of Medicine and Chief of Myeloma Program and Experimental Therapeutics Program at